Empagliflozin (Type 2 Diabetes) - Forecast and Market Analysis to 2022SummaryGlobalData has released its new report, 'Empagliflozin (Type 2 Diabetes) - Forecast and Market Analysis to 2022'. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.Empagliflozin belongs to a newly emerging class of SGLT-2 inhibitors and it is being investigated in Phase III clinical trials for the oral treatment of type 2 diabetes jointly by Eli Lilly and Boehringer Ingelheim.Scope- Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnos...